It is believed that worldwide a population of about 170 million individuals are infected with HCV i.e. Hepatitis C Virus. There are six genotypes of the contagion that have been identified. Genotypes 1, 2, and 3 are the sources of most of the information on chronic Hepatitis C. These genotypes are most common in the United State and Europe. The genotype 4 has been widespread in Africa and the Middle East.
This genotype, Genotype 4 of Hepatitis C, is the 4th most common strain on a worldwide platform. It has a count of almost 90% of the population i.e. approx. 6,030,000 people among the Hepatitis C cases in Egypt alone. The overall cases of Hepatitis C in Egypt are believed to be about 6.7 million. The United States has its 1% of the overall population suffering from Hepatitis C genotype. This genotype has the most subtypes viz. a to z. During 1960’s to 1980’s when the mass campaign was held to control the dreadful schistosomiasis contagion, transferred from snails to humans who work in rice fields, in Egypt caused the rise and spread of genotype 4 of Hepatitis C. This happened because in this time period of the campaign being held the patients of schistosomiasis were injected with medications using injections that were used and unsterilized as well. The ongoing treatment for Hepatitis C genotype 4 is Sofosbuvir, ribavirin and pegylated interferon. The basic treatment for the genotype is of 12 weeks but the duration may vary depending on various factors and the individual. The cure rates are about 96%. There are many upcoming medications for treating the genotype effectively.
In cases of adult patients with chronic Hepatitis C genotype 4, the treatments are similar for treatment-naïve patients with or without cirrhosis. However, glecaprevir-pibrentasvir is an exception where it is used for a duration of 8 weeks for patients who do not have cirrhosis and 12 weeks for patients with cirrhosis.